Welcome to PRECIDENTD!

Thank you for your interest in PRECIDENTD. In this study, people with diabetes are partnering with doctors and study teams to help advance our understanding of diabetes medications that lower the risk of heart disease.

Why This Study is Important

Having type 2 diabetes doubles your risk for heart disease.

There are two types (classes) of diabetes medications that have been shown to reduce that risk, SGLT2 inhibitors and GLP-1 receptor agonists. It is not known how these types compare to each other, or whether the combination lowers heart disease more effectively than one type alone.

How the Study Works

If you choose to participate, a computer will randomly assign you to take an FDA-approved medication to treat type 2 diabetes:

• An SGLT2 inhibitor such as Jardiance, Farxiga, Invokana

• A GLP-1 receptor agonist such as Victoza, Trulicity, Ozempic, Rybelsus

Or, both classes of medication 

Our study team will work with your regular healthcare provider to fit the study medication into your usual diabetes care. Your current diabetes medications may be adjusted. 

PRECIDENTD Study Overview

Study Eligibility

PRECIDENTD may be for you if you are:


For more information about the medications used and the PRECIDENTD study, click the button below.


For more information on the study, how to participate, and our study locations,
click the button below to go directly to our “Contact Us” page